GreenLight Biosciences and Bayer CropScience announced a new partnership to explore applications of GreenLight's proprietary cell-free technologies to increase the productivity of potential manufacturing processes. GreenLight's assets can enable a new safe, fast, energy efficient and economical way of manufacturing crop protection products through bacteria which have been engineered to produce enzymes for cell-free chemical synthesis processes. Financial terms of the agreement between GreenLight Biosciences and Bayer.
GreenLight Biosciences Holdings
Equities
GRNA
US39536G1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |